Vincerx Pharma Inc Quick Ratio (VINC) starting from the first quarter 2025 to first quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Vincerx Pharma Inc   (VINC)

Vincerx Pharma Inc 's Quick Ratio

VINC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Vincerx Pharma Inc 's Cash & cash equivalent, this led to improvement in Vincerx Pharma Inc 's Quick Ratio to 1.69, Quick Ratio remained below Vincerx Pharma Inc average.

Within Major Pharmaceutical Preparations industry 313 other companies have achieved higher Quick Ratio than Vincerx Pharma Inc in first quarter 2025. While Quick Ratio total ranking has improved so far during the Q1 2025 to 1203, from total ranking in the fourth quarter 2024 at 1708.

Explain Quick Ratio?
How much Cash & cash equivalents VINC´s has?
What are VINC´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VINC Quick Ratio (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1
Y / Y Current Liabilities Change -75.36 % -5.78 % -38.68 % -41.77 % -0.73 %
Y / Y Cash & cash equivalent Change -13.17 % -60.98 % -51.51 % -40.35 % -87.15 %
Quick Ratio MRQ 1.69 0.94 1.86 3.06 0.48
VINC's Total Ranking # 1203 # 1708 # 988 # 365 # 1658
Seq. Current Liabilities Change -50.39 % -2.64 % 1.73 % -49.86 % 89.72 %
Seq. Cash & cash equivalent Change -11.03 % -50.56 % -38.19 % 219.35 % -60.02 %



Quick Ratio first quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 314
Healthcare Sector # 542
Overall Market # 1203


Quick Ratio Statistics
High Average Low
20.98 4.66 0.48
(Mar 31 2020)   (Mar 31 2024)




Financial Statements
Vincerx Pharma Inc 's Current Liabilities $ 3 Millions Visit VINC's Balance sheet
Vincerx Pharma Inc 's Cash & cash equivalent $ 4 Millions Visit VINC's Balance sheet
Source of VINC's Sales Visit VINC's Sales by Geography


Cumulative Vincerx Pharma Inc 's Quick Ratio

VINC's Quick Ratio for the trailling 12 Months

VINC Quick Ratio

 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -45.51 % -22.29 % -28.72 % -21.96 % -14.97 %
Y / Y Cash & cash equivalent TTM Growth -45.76 % -63.76 % -68.45 % -70.35 % -72.37 %
Quick Ratio TTM 1.92 1.37 1.64 1.81 1.93
Total Ranking TTM # 3157 # 3249 # 3317 # 1699 # 2294
Seq. Current Liabilities TTM Growth -30.05 % -1.2 % -11.25 % -11.17 % -0.23 %
Seq. Cash & cash equivalent TTM Growth -1.84 % -17.6 % -19.48 % -16.71 % -34.41 %

Quick ratio ranking by company, industry and sector >> Back to VINC Financial Strength Comparisons >> Go to Compare VINC Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Vincerx Pharma Inc 's average Cash & cash equivalent, this led to increase in in Vincerx Pharma Inc 's Quick Ratio to 1.92, Quick Ratio remained below VINC average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 422 other companies have achieved higher Quick Ratio than Vincerx Pharma Inc . While Quick Ratio overall ranking has improved so far to 3157, from total ranking during the twelve months ending fourth quarter 2024 at 3249.

Explain Quick Ratio?
How much Cash & cash equivalents VINC´s has?
What are VINC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 423
Healthcare Sector # 858
Within the Market # 3157


trailing twelve months Quick Ratio Statistics
High Average Low
7.74 3.51 0.01
(Sep 30 2022)  




Companies with similar Quick Ratio in the quarter ending Mar 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2025 MRQ Cash & cash equivalentMar 31 2025 MRQ Current Liabilities
Transcode Therapeutics Inc   4.65 $ 11.681  Millions$ 2.510  Millions
Mural Oncology Plc  4.65 $ 107.682  Millions$ 23.153  Millions
United Therapeutics Corporation  4.60 $ 3,321.300  Millions$ 721.500  Millions
Lantern Pharma Inc   4.60 $ 19.722  Millions$ 4.286  Millions
Kiora Pharmaceuticals Inc   4.57 $ 24.106  Millions$ 5.275  Millions
Bullfrog Ai Holdings Inc   4.53 $ 3.802  Millions$ 0.839  Millions
Maravai Lifesciences Holdings Inc   4.51 $ 285.053  Millions$ 63.158  Millions
Kairos Pharma Ltd   4.49 $ 3.616  Millions$ 0.805  Millions
Q32 Bio Inc   4.49 $ 65.483  Millions$ 14.579  Millions
Arvinas Inc   4.46 $ 954.300  Millions$ 214.000  Millions
Arcturus Therapeutics Holdings Inc   4.39 $ 216.948  Millions$ 49.409  Millions
Damora Therapeutics Inc   4.33 $ 11.939  Millions$ 2.755  Millions
Hutchmed china Limited  4.33 $ 1,367.275  Millions$ 315.775  Millions
Milestone Pharmaceuticals Inc   4.32 $ 55.958  Millions$ 12.963  Millions
Sinovac Biotech Ltd  4.31 $ 6,639.502  Millions$ 1,540.365  Millions
Cocrystal Pharma Inc   4.27 $ 6.921  Millions$ 1.622  Millions
Enanta Pharmaceuticals Inc  4.21 $ 193.375  Millions$ 45.947  Millions
Theravance Biopharma inc   4.15 $ 130.855  Millions$ 31.502  Millions
Rain Enhancement Technologies Holdco Inc   4.15 $ 15.273  Millions$ 3.683  Millions
Xoma Royalty Corporation  4.14 $ 90.265  Millions$ 21.802  Millions
Sellas Life Sciences Group Inc   4.14 $ 28.497  Millions$ 6.888  Millions
Arrowhead Pharmaceuticals Inc   4.13 $ 911.700  Millions$ 220.541  Millions
Vyne Therapeutics Inc   4.11 $ 50.272  Millions$ 12.228  Millions
Bridgebio Pharma Inc   4.06 $ 540.599  Millions$ 133.069  Millions
Pasithea Therapeutics Corp   4.03 $ 5.341  Millions$ 1.326  Millions
Cadrenal Therapeutics Inc  3.99 $ 7.336  Millions$ 1.840  Millions
Bioharvest Sciences Inc   3.98 $ 23.025  Millions$ 5.787  Millions
Sol gel Technologies Ltd   3.89 $ 23.999  Millions$ 6.171  Millions
Nextcure Inc   3.80 $ 21.827  Millions$ 5.740  Millions
Aquestive Therapeutics Inc   3.75 $ 68.657  Millions$ 18.298  Millions

Date modified: 2026-08-29T17:41:27+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.